ENDRA Life Sciences (NASDAQ:NDRA) Releases Earnings Results, Misses Estimates By $0.01 EPS

ENDRA Life Sciences (NASDAQ:NDRA) announced its quarterly earnings data on Wednesday. The company reported ($0.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.01), Zacks reports.

ENDRA Life Sciences Trading Down 22.5 %

NDRA stock traded down $0.01 during midday trading on Friday, hitting $0.04. 24,017,083 shares of the company’s stock were exchanged, compared to its average volume of 9,370,943. ENDRA Life Sciences has a 1-year low of $0.04 and a 1-year high of $2.79. The business has a 50-day simple moving average of $0.09 and a two-hundred day simple moving average of $0.45. The stock has a market capitalization of $2.92 million, a PE ratio of -0.03 and a beta of 0.82.

Shares of ENDRA Life Sciences are going to reverse split on Tuesday, August 20th. The 1-50 reverse split was announced on Friday, August 16th. The number of shares owned by shareholders will be adjusted after the market closes on Monday, August 19th.

Wall Street Analysts Forecast Growth

Separately, Ascendiant Capital Markets lowered their price target on ENDRA Life Sciences from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Friday, June 7th.

ENDRA Life Sciences Company Profile

ENDRA Life Sciences Inc develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is developing thermo-acoustic enhanced ultrasound technology that uses radio frequency pulses to generate ultrasonic waves in tissue to create high-contrast images for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion.